1. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. Issue 1 (10th December 2021) Authors: Martin, Thomas; Krishnan, Amrita; Yong, Kwee; Weisel, Katja; Mehra, Maneesha; Nair, Sandhya; Qi, Keqin; Londhe, Anil; Diels, Joris; Crivera, Concetta; Jackson, Carolyn C.; Olyslager, Yunsi; Vogel, Martin; Schecter, Jordan M.; Banerjee, Arnob; Valluri, Satish; Usmani, Saad Z.; Berdeja, Jesus G.; J... Journal: EJHaem Issue: Volume 3:Issue 1(2022) Page Start: 97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Comprehensive BCMA Expression Profiling in Adult Normal Human Brain Suggests a Low Risk of On-target Neurotoxicity in BCMA-targeting Multiple Myeloma Therapy. (April 2022) Authors: Marella, Mathieu; Yao, Xiang; Carreira, Vinicius; Bustamante, Marta F.; Clark, H. Brent; Jackson, Carolyn C.; Zudaire, Enrique; Schecter, Jordan M.; Glover, Tynisha D.; Shenton, Jacintha; Cornax, Ingrid Journal: Journal of histochemistry and cytochemistry Issue: Volume 70:Number 4(2022) Page Start: 273 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019. (23rd July 2021) Authors: Hester, Laura L.; Gifkins, Dina M.; M. Bellew, Kevin; Vermeulen, Jessica; Schecter, Jordan M.; Strony, John; Dishy, Victor; Weiss, Brendan M. Journal: European journal of haematology Issue: Volume 107:Number 4(2021) Page Start: 428 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study. (31st March 2019) Authors: Plesner, Torben; Arkenau, Hendrik‐Tobias; Gay, Francesca; Minnema, Monique C.; Boccadoro, Mario; Moreau, Philippe; Cavenagh, Jamie; Perrot, Aurore; Laubach, Jacob P.; Krejcik, Jakub; Ahmadi, Tahamtan; de Boer, Carla; Chen, Diana; Chiu, Christopher; Schecter, Jordan M.; Richardson, Paul G. Journal: British journal of haematology Issue: Volume 186:Number 3(2019) Page Start: e35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. (3rd October 2021) Authors: Martin, Tom; Usmani, Saad Z.; Schecter, Jordan M.; Vogel, Martin; Jackson, Carolyn C.; Deraedt, William; Tian, Hong; Yeh, Tzu-min; Banerjee, Arnob; Pacaud, Lida; Garrett, Ashraf; Haltner, Anja; Cameron, Chris; Van Sanden, Suzy; Diels, Joris; Valluri, Satish; Samjoo, Imtiaz A. Journal: Current medical research and opinion Issue: Volume 37:Number 10(2021) Page Start: 1779 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma. (3rd October 2022) Authors: Costa, Luciano J.; Hari, Parameswaran; Berdeja, Jesus G.; De Stefano, Valerio; Gay, Francesca; Hooper, Becky; Bartlett, Meaghan; Haltner, Anja; Rosta, Emily; Kumar, Shaji; Martin, Thomas; Mateos, Maria-Victoria; Moreau, Philippe; Usmani, Saad Z.; Olyslager, Yunsi; Schecter, Jordan M.; Roccia, Tit... Journal: Current medical research and opinion Issue: Volume 38:Number 10(2022) Page Start: 1759 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1). Issue 6 (20th February 2023) Authors: Mi, Jian-Qing; Zhao, Wanhong; Jing, Hongmei; Fu, Weijun; Hu, Jianda; Chen, Lijuan; Zhang, Yiwen; Yao, Dan; Chen, Diana; Schecter, Jordan M.; Yang, Fan; Tian, Xiaochen; Sun, Huabin; Zhuang, Sen Hong; Ren, Jimmy; Fan, Xiaohu; Jin, Jie; Niu, Ting; Chen, Sai-Juan Journal: Journal of clinical oncology Issue: Volume 41:Issue 6(2023) Page Start: 1275 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Response to "The Role of FcRn in the Pharmacokinetics of Biologics in Patients with Multiple Myeloma". Issue 6 (29th July 2017) Authors: Xu, Xu Steven; Schecter, Jordan M.; Jansson, Richard; Yan, Xiaoyu Journal: Clinical pharmacology & therapeutics Issue: Volume 102:Issue 6(2017) Page Start: 905 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. (2nd January 2023) Authors: Martin, Tom; Usmani, Saad Z.; Schecter, Jordan M.; Roccia, Tito; Jackson, Carolyn C.; Deraedt, William; Yeh, Tzu-min; Banerjee, Arnob; Pacaud, Lida; Garrett, Ashraf; Bartlett, Meaghan; Haltner, Anja; Van Sanden, Suzy; Diels, Joris; Valluri, Satish; Samjoo, Imtiaz A. Journal: Current medical research and opinion Issue: Volume 39:Number 1(2023) Page Start: 81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗